In their hands, synthetic peptide vaccines consisting of a minimal CD8+ T cell epitope and either a CD4+ T cell neo-epitope or universal helper peptide PADRE protected equally well against a subsequent tumor challenge.59 This evidence concerns the gene CD8A and neoplasm.